Institute for Clinical and Economic Review Releases Draft Evidence Report on Therapies for Cystic Fibrosis
February 21, 2020
February 21, 2020
BOSTON, Massachusetts, Feb. 21 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for cystic fibrosis. ICER's report focuses on elexacaftor/tezacaftor/ivacaftor (TrikaftaTM, Vertex). ICER also examined new data that has become available since its May 2018 review of three other cystic fib . . .
The Institute for Clinical and Economic Review (ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for cystic fibrosis. ICER's report focuses on elexacaftor/tezacaftor/ivacaftor (TrikaftaTM, Vertex). ICER also examined new data that has become available since its May 2018 review of three other cystic fib . . .